Biophytis to Conduct Phase 2/3 Trial of Investigational Sarconeos for COVID-19

Biophytis is set to conduct a phase 2/3 trial in the U.S. of its investigational drug Sarconeos for acute respiratory failure associated with COVID-19.

The initial trial will assess the treatment’s safety and efficacy in 50 hospitalized COVID-19 patients. The second phase will evaluate the efficacy of the drug in 300 additional patients.

Biophytis is developing Sarconeos for the treatment of sarcopenia, a skeletal muscle disorder, and Duchenne muscular dystrophy.